GSK (NYSE: GSK) has licensed SA030, a Phase I siRNA oligonucleotide targeting activin receptor-like kinase 7 (ALK7), from Suzhou-based SiranBio in a worldwide exclusive agreement covering all territories outside mainland China, Hong Kong, Macau, and Taiwan.
The deal grants GSK rights to a long-acting, adipocyte-directed siRNA candidate described by SiranBio as a potential first-in-disease asset for cardiometabolic disease, with applications across chronic kidney, liver, and lung conditions. SiranBio will retain responsibility for completing Phase I development before handing over full development, regulatory, and commercialization rights to GSK ex-Greater China.
GSK will pay a USD 55 million upfront fee plus success-based development, regulatory, and commercial milestones totaling up to USD 1.005 billion, along with tiered royalties on net sales in licensed territories.
Deal context
SA030 targets ALK7, a TGF-beta superfamily receptor expressed in adipose tissue that regulates lipolysis and fat storage. Preclinical evidence, including published work on ALK7 biology, indicates that suppressing ALK7 activity in visceral adipose tissue promotes fat breakdown while preserving lean mass — a profile that distinguishes it mechanistically from GLP-1 receptor agonists, which are associated with some degree of lean mass loss. SiranBio describes SA030 as having a complementary and distinct mechanism to GLP-1 agonists and SGLT2 inhibitors, positioning it for potential combination use. The drug is currently the subject of a Phase I clinical trial in overweight or obesity.
Interest in ALK7 has accelerated alongside broader industry focus on the Activin E/ALK7 signaling axis, which regulates adipose tissue energy homeostasis. In addition to receptor-targeting approaches such as SA030, several companies are pursuing therapies aimed at INHBE, the gene encoding the circulating ligand Activin E. Arrowhead Pharmaceuticals is currently the leading clinical player in the field with both its adipocyte-targeted ARO-ALK7 program and liver-directed ARO-INHBE candidate in Phase I/IIa development for obesity and metabolic disease. Arrowhead reported interim 2026 data showing reductions in visceral fat and early evidence of lean-mass preservation, including what it described as the first demonstration of adipocyte gene silencing in humans using an RNAi therapeutic. Other RNA medicine developers, including Wave Life Sciences, have also disclosed research efforts involving the pathway as interest grows in combination therapies designed to complement GLP-1-based obesity treatments.